BENEFIT FROM ANTI-EGFR THERAPY IN KRAS, BRAF, NRAS, PI3KCA "ALL WILD TYPE", EGFR POSITIVE COLORECTAL CANCER PATIENTS.

被引：0
|
作者：
De Maglio, Giovanna [1 ]
Aprile, Giuseppe [2 ]
Foltran, Luisa [2 ]
Masiero, Elena [1 ]
Lutrino, Stefania [2 ]
Cardellino, Giovanni [2 ]
Fontanella, Caterina [2 ]
Fasola, Gianpiero [2 ]
Pizzolitto, Stefano [1 ]
机构：
[1] Univ Hosp, Dept Pathol, Udine, Italy
[2] Univ Hosp, Dept Oncol, Udine, Italy
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：v107 / v107
页数：1
相关论文
共 50 条
  • [1] Gain of ALK gene copy number to predict lack of response to anti-EGFR treatment in advanced chemorefractory colorectal cancer (CRC) with KRAS/NRAS/BRAF/PI3KCA wild-type status
    Pietrantonio, Filippo
    Tessari, Anna
    Miceli, Rosalba
    Biondani, Pamela
    Perrone, Federica
    Testi, Adele
    Tamborini, Elena
    Pelosi, Giuseppe
    Mariani, Luigi
    Fanetti, Giuseppe
    Gevorgyan, Arpine
    Bossi, Ilaria
    Di Bartolomeo, Maria
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines
    Kumar, S. Sree
    Price, T.
    Hardingham, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S493 - S493
  • [3] PREDICTIVE MOLECULAR BIOMARKERS IN COLORECTAL CANCER: IS KRAS AND BRAF WILD TYPE STATUS REQUIRED FOR ANTI-EGFR THERAPY?
    Marchoudi, N.
    Joutei, H. Amrani Hassani
    Jouali, F.
    Fekkak, J.
    Rhaissi, H.
    ANTICANCER RESEARCH, 2014, 34 (10) : 6048 - 6048
  • [4] Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo, Sergio
    Bronte, Giuseppe
    Fanale, Daniele
    Corsini, Lidia
    Silvestris, Nicola
    Santini, Daniele
    Gulotta, Gaspare
    Bazan, Viviana
    Gebbia, Nicola
    Fulfaro, Fabio
    Russo, Antonio
    CANCER TREATMENT REVIEWS, 2010, 36 : S56 - S61
  • [5] EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy
    Uhlyarik, A.
    Piurko, V
    Vizkeleti, L.
    Papai, Zs
    Raso, E.
    Lahm, E.
    Kiss, E.
    Sikter, M.
    Vachaja, J.
    Kenessey, I
    Timar, Jozsef
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (03) : 1429 - 1434
  • [6] New predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
    Kishiki, Tomokazu
    Masaki, Tadahiko
    Matsuoka, Hiroyoshi
    Kojima, Koichiro
    Asoh, Nobuyoshi
    Beniya, Ayumi
    Sakamoto, Yoshihiro
    Mori, Toshiyuki
    Abe, Nobutsugu
    CANCER SCIENCE, 2018, 109 : 1378 - 1378
  • [7] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    Jose A. García-Sáenz
    Javier Sastre
    Eduardo Díaz-Rubio García
    Clinical and Translational Oncology, 2009, 11 : 737 - 747
  • [8] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    Garcia-Saenz, Jose A.
    Sastre, Javier
    Diaz-Rubio Garcia, Eduardo
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (11): : 737 - 747
  • [9] BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer
    Chen Mao
    Ru-Yan Liao
    Qing Chen
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 1293 - 1294
  • [10] BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer
    Mao, Chen
    Liao, Ru-Yan
    Chen, Qing
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (08) : 1293 - 1294
12345